RALEIGH, North Carolina, September 13, 2010 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that two of its leading drug safety experts will present at the 4th annual World Drug Safety Congress to be held in London 14 -17 September 2010. PRA will also host a conference exhibit.
Dr. Sabine Richter, PRA's Vice President of Safety Risk Management (SRM) and a conference chair, will make the opening remarks for the Thursday morning session on pre-clinical and clinical safety strategies. Dr. Angelika Schneider, Director of PRA's Drug Safety Centers in Europe, Asia-Pacific and Africa, will discuss the challenges of global compliance in the current regulatory environment in her Thursday afternoon session. She will also review a PRA-developed repository that contains the diverse safety reporting requirements for more than 60 countries.
At booth 11, PRA drug safety managers will be available to discuss PRA's successful experience in SRM engagements for sponsor.
As vice president, Dr. Richter is responsible for all aspects of PRA's SRM services. To ensure consistent high performance and regulatory compliance, Dr. Richter has developed robust procedures and quality control measures. Dr. Schneider has nearly 15 years of experience in clinical research and pharmacovigilance. Over the last six years, she has led several large pharmacovigilance projects both in the pre- and post-marketing settings.
PRA provides safety and risk management services during the entire product life cycle. Our SRM team of more than 110 experts is available to our clients for consultancy as well as routine and specialty pharmacovigilance services. Our drug safety centers are based in Mannheim, Germany; Charlottesville, VA (US); and Sao Paulo, Brazil.
For more information about the World Drug Safety Congress, navigate to http://www.praintl.com and click on Events.
About PRA International
PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 38 global offices.
PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.
SOURCE: PRA International
CONTACT: Roger Boutin, Director of Marketing of PRA International, Inc.,+1-434-951-3924